TFG‑001: 3D Neural Microtissue Cell Therapy for Parkinson’s Disease: new preclinical data presented at the 7th World Parkinson Congress in Phoenix, Arizona

– TreeFrog Therapeutics presented new preclinical data on its lead program, TFG-001, a 3D Neural Microtissue Cell Therapy for Parkinson’s Disease at the World Parkinson Congress on May 27. –

BORDEAUX, France / May 28th, 2026 – TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, presented new preclinical data on TFG-001 at the 7th World Parkinson’s Conference.

Presented by Nicolas Prudon, PhD, Parkinson Lead Scientist at TreeFrog Therapeutics, the poster showed that TFG-001, our 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate.

TFG-001 is designed to enhance post-transplantation integration and reinnervation. Unlike single-cell suspensions, which must re-establish connections with each other and the host tissue, its pre-organized 3D dopaminergic network, comprising both progenitors and neurons, facilitates more efficient integration and markedly improves reinnervation capacity.

Best-in-class characteristics of TFG-001:

Rapid Dopamine Release: TFG-001 demonstrates dopamine release as early as 48 hours, versus ~28 days reported by benchmark cell therapies[i]^,[ii]
Extensive Striatal Reinnervation: In vivo studies show that the graft successfully integrates and reinnervates target regions of the brain in the advanced translational Parkinson’s disease models.
Accelerated Motor Recovery: Preclinical models achieved functional motor recovery in roughly 13 weeks, significantly faster than the 17–28 weeks reported by existing benchmark cell therapies ^{i,ii,[iii],[iv]}(Piao et al., 2021; Hiramatsu et al., 2022; Kirkeby et al., 2023; Park et al., 2024).

Beyond its biological advantages, TFG-001 addresses some of the major manufacturing bottlenecks that have historically limited cell therapies. TFG-001 is manufactured using TreeFrog’s proprietary C-Stem™ platform, a closed, bioreactor-based system centered on capsule technology, designed for scalable cell expansion and differentiation under GMP-compliant conditions.

With approximately 1.3 million patients in the EU and 1.0 million in the US, the need for an effective, scalable regenerative therapy for Parkinson’s disease is massive. TFG-001 will be ready for a Clinical Trial Application (CTA) in 2027.

TreeFrog Therapeutics is exploring co-development and commercialization of TFG-001.

About TreeFrog Therapeutics

TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry – producing and differentiating cells of quality at unprecedented scale, cost-effectively. To realize their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players in other areas. In the last 3 years, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of the C-Stem^TM platform and establish strategic alliances with leading academic, biotech and industry players.

www.treefrog.fr